Advances in Pharmacotherapy for Neuroblastoma Publisher Pubmed



Pezeshki PS^{1, 2} ; Moeinafshar A^{1, 2} ; Ghaemdoust F^{1, 2} ; Razi S^{1, 3, 4} ; Keshavarzfathi M^{1, 2, 4} ; Rezaei N^{4, 5, 6} Show Affiliations
Source: Expert Opinion on Pharmacotherapy Published:2021

Abstract

Introduction: Neuroblastoma is the most prevalent cancer type diagnosed within the first year after birth and accounts for 15% of deaths from pediatric cancer. Despite the improvements in survival rates of patients with neuroblastoma, the incidence of the disease has increased over the last decade. Neuroblastoma tumor cells harbor a vast range of variable and heterogeneous histochemical and genetic alterations which calls for the need to administer individualized and targeted therapies to induce tumor regression in each patient. Areas covered: This paper provides reviews the recent clinical trials which used chemotherapeutic and/or targeted agents as either monotherapies or in combination to improve the response rate in patients with neuroblastoma, and especially high-risk neuroblastoma. It also reviews some of the prominent preclinical studies which can provide the rationale for future clinical trials. Expert opinion: Although some distinguished advances in pharmacotherapy have been made to improve the survival rate and reduce adverse events in patients with neuroblastoma, a more comprehensive understanding of the mechanisms of tumorigenesis, resistance to therapies or relapse, identifying biomarkers of response to each specific drug, and developing predictive preclinical models of the tumor can lead to further breakthroughs in the treatment of neuroblastoma. © 2021 Informa UK Limited, trading as Taylor & Francis Group.